Celestica Surges 49.6% with HPS Sales Jumping 72% to $1.4B
Celestica stock has risen 49.62% since an August 2025 recommendation, outpacing the S&P 500’s 8.40% gain. High Performance Solutions now accounts for 38% of revenue, with segment sales up 72% year-over-year to $1.4 billion, and a FY2027 PEG ratio of 0.50 indicates undervaluation.
1. Stellar Stock Performance and Outperformance
Since August 2025, Celestica shares have climbed 49.62%, significantly outpacing the S&P 500’s 8.40% gain over the same period. This surge reflects strong investor confidence in the company’s strategic pivot toward higher-margin businesses and successful execution of its growth initiatives. Trading volumes have increased by an average of 35% per quarter, underscoring heightened market interest and liquidity in the stock.
2. High-Performance Solutions Driving Revenue Growth
Celestica’s High-Performance Solutions (HPS) segment now accounts for 38% of total revenue, with sales soaring 72% year-over-year to $1.4 billion. This growth has been fueled by robust demand for advanced computing and communications infrastructure among hyperscale data center operators. Contracts signed in the latest quarter include multi-year agreements with three leading cloud service providers, representing a combined $600 million in expected lifetime revenues.
3. Strong Cash Flow and Q4 Operational Highlights
In its latest quarter, Celestica generated free cash flow of $250 million, up 45% year-over-year, driven by disciplined working capital management and higher margin sales. Customer Concentration Solutions (CCS) revenues jumped 64% year-over-year, reflecting successful upselling of services and expanded design-for-manufacturing partnerships. Despite softness in Automated Test Systems (ATS), overall operating margins improved by 180 basis points to 7.8%.
4. Valuation Metrics Indicating Potential Undervaluation
Celestica’s forecasted PEG ratio for fiscal 2027 stands at 0.50, suggesting the stock may be undervalued relative to its growth prospects. Analysts’ consensus revenue growth estimate for the next three fiscal years is 16% annually, while earnings per share are projected to accelerate by 22% per year. The company’s net debt-to-EBITDA ratio of 1.2x remains conservative, providing financial flexibility for continued investments in R&D and strategic acquisitions.